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age utility of asthma pediatric asthma patients.
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OBJECTIVES: To gain utility values for asthmatic pa-
tients, self-administered direct TTO questions may seem
to be a simple option. This study examined reported
TTO values by disease severity groups, and the relation-
ship between other health status measures, and with age.
METHODS: 228 consecutive adult outpatients and inpa-
tients at four sites in Hungary participated in the study.
Doctors had to report GINA severity group and lung
function values. Patients had to fill in three QoL ques-
tionnaires and a direct TTO question that offered a
choice between 20 years in current health or shorter
length of life in perfect health. Statistical analysis applied
F-statistics. RESULTS: Mean TTO values were 0.99,
0.96, 0.82, 0.73 in the four severity groups, respectively.
These were higher than corresponding EQ-5Dindex re-
sults of 0.93, 0.76, 0.65, 0.52. Correlation coefficients
between TTO values and EQ-5Dindex, EQ-5Dvas, SF-
36(PCS), SF-36(MCS), SGRQ, and FEV1% were 0.40,
0.40, 0.34, 0.25, 0.36, and 0.36, respectively. Age ex-
plained 23% of differences in TTO values after control-
ling for asthma severity. Within severity groups 4 and 3,
patients over 50 reported TTO values lower by 0.21 and
0.20 than those below this age. These differences were
larger than corresponding differences in EQ-5D index
values suggesting that direct TTO responses may incor-
porate different concepts of remaining life years of the
older. Results were statistically significant (p  0.0001).
CONCLUSIONS: Utility values gained from direct TTO
questions can lead to higher scores than generic utility-
based questionnaires, low correlation values with other
measures, and to biases in patient groups of heteroge-
neous age.
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OBJECTIVES: To develop a practical and scientifically
rigorous, patient-based outcome questionnaire to evalu-
ate symptoms in community-acquired pneumonia (CAP).
METHODS: The CAP-Symptom questionnaire (CAP-
Sym) is an 18-item, interviewer-administered question-
naire that measures the bothersomeness of 18 symptoms
during the past 24 hours using a 6-point Likert scale. We
used gold-standard psychometric methods to comprehen-
sively evaluate the acceptability, reliability, validity and
responsiveness of the CAP-Sym in field testing involving
556 patients in 13 countries. The development and vali-
dation of the CAP-Sym were carried out as part of the
CAP 2000 study, a multicentre, multinational, prospec-
tive, randomised, double-blind study to compare the ef-
fectiveness of moxifloxacin oral tablets to standard oral
treatment regimes in patients with CAP. RESULTS: Field
testing in all countries confirmed the acceptability (item
non-response, item endorsement frequencies, item/scale
floor and ceiling effects), reliability (internal consistency,
item-total and inter-item correlations, test-retest reliabil-
ity), validity (content, construct, convergent, discrimi-
nant, known groups) and responsiveness of the CAP-
Sym. CONCLUSIONS: The CAP-Sym is a practical and
scientifically sound patient-based outcome measure that
can be used to evaluate CAP-related symptoms in clinical
trials or clinical audit. The disease-specific CAP-Sym
shows preliminary evidence of being more responsive
than the generic SF-36 as a measure of outcome in CAP.
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OBJECTIVE: To forecast the discounted costs and clini-
cal consequences of inhaled corticosteroids (ICS) in a
population of adults with mild-to-moderate asthma.
METHODS: We developed a Markov, state-transition
simulation of asthma patient care and its pharmacoeco-
nomic impact. We employed this framework to compare
quick relievers (e.g., b-agonists) on an as-needed basis to
quick relievers plus ICS therapy targeted to one of three
severity sub-populations. State-space dimensions included
patient age, clinical history, and lung dysfunction (mea-
sured via forced expiratory volume in one second, FEV1).
Risk functions were estimated from symptom, exacerba-
tion, and hospitalization rates obtained from literature
reviews and analyses of primary, cross-sectional data. Sys-
tematic review of published trials yielded 16 eligible stud-
ies and produced the following outcome ranges for sensi-
tivity analysis: 1%–21% improvement in FEV1; monthly
costs of $14–$76; and 0%–4% probability of major tox-
icity. Societal costs were derived from published economic
studies of inpatient and outpatient asthma. We collected
preference weights (using standard gambles, time trade-
offs, and the Health Utilities Index) in a cross-sectional
